Drugs / QL1101
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06232902 | Jun → Nov 2024 | neoplasm | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05585281 | Jul 2023 → Nov 2025 | ovarian cancer | Yongpeng Wang | Unknown | No outcome recorded |
| Phase 2 | NCT05883176 | Jun 2023 → May 2025 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03169335 | Mar 2017 → Jun 2018 | non-small cell lung carcinoma | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QL 1101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05883176 ↗ |
| Action | Inhibit | “anti-VEGF” NCT05883176 ↗ |
| Route | Intravenous | “via a 30-minute IV infusion” NCT05585281 ↗ |